Geographic atrophy treatment Izervay receives permanent J-code
Click Here to Manage Email Alerts
Key takeaways:
- Izervay received a permanent J-code from CMS.
- The code, J2782, goes into effect April 1.
CMS has assigned a permanent J-code for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric Bio.
The new code for Izervay (avacincaptad pegol intravitreal solution) for geographic atrophy (GA), J2782, is effective April 1.
“Geographic atrophy is a progressive disease that can lead to irreversible vision loss, and early treatment can have a significant impact on patients’ lives,” Michael Petroutsas, head of U.S. commercial for Astellas Pharma, Iveric’s parent company, said in the release. “Receiving a permanent J-code in the U.S. supports our efforts to increase timely patient access to Izervay, the first and only FDA-approved GA treatment to demonstrate a statistically significant reduction in the rate of GA progression in just 12 months across two pivotal trials.”
More than 40,000 vials of Izervay have been distributed to physician practices since its U.S. launch in September 2023, the release said.
Read more about
Click Here to Manage Email Alerts